Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study Reports Strong Results For Atrial Fibrillation Treatment With Ablation

This article was originally published in The Gray Sheet

Executive Summary

Nearly three-fourths of all patients with chronic atrial fibrillation could be free of symptoms one year later if they undergo circumferential pulmonary-vein ablation, according to a study in the March 2 issue of The New England Journal of Medicine

You may also be interested in...



AF Ablation Lacks Evidence, Despite Growing Adoption – TEC Assessment

A recent BlueCross BlueShield Association assessment of atrial fibrillation ablation echoes widespread belief among payors and doctors that the technique is still evolving

AF Ablation Lacks Evidence, Despite Growing Adoption – TEC Assessment

A recent BlueCross BlueShield Association assessment of atrial fibrillation ablation echoes widespread belief among payors and doctors that the technique is still evolving

FDA Considers Easing Industry Burden In AF Ablation Catheter Trial Design

FDA may be willing to accept a reduction of symptoms as the primary endpoint for atrial fibrillation ablation catheter clinical trials, according to CDRH Cardiac Electrophysiology & Monitoring Devices Branch Medical Officer Randall Brockman, MD

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel